152 related articles for article (PubMed ID: 25161997)
1. OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC.
Hao Y; Liu J; Wang P; Wang F; Yu Z; Li M; Chen S; Ning F
Int J Genomics; 2014; 2014():846142. PubMed ID: 25161997
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism -433 C>T of the Osteopontin gene is associated with the susceptibility to develop gliomas and their prognosis in a Chinese cohort.
Shen Z; Chen B; Hou X; Chen P; Zhao G; Fan J
Cell Physiol Biochem; 2014; 34(4):1190-8. PubMed ID: 25277531
[TBL] [Abstract][Full Text] [Related]
3. OPN -443C>T genetic polymorphism and tumor OPN expression are associated with the risk and clinical features of papillary thyroid cancer in a Chinese cohort.
Mu G; Wang H; Cai Z; Ji H
Cell Physiol Biochem; 2013; 32(1):171-9. PubMed ID: 23867349
[TBL] [Abstract][Full Text] [Related]
4. The OPN gene polymorphism confers the susceptibility and response to Ara-C based chemotherapy in Chinese AML patients.
Zhang R; Yang W; Li YC; Zhang GJ; Yao K; Hu R; Wu B
Cell Physiol Biochem; 2015; 35(1):175-83. PubMed ID: 25591760
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Xiong L; Cheng J; Gao J; Wang J; Liu X; Wang L
Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
[TBL] [Abstract][Full Text] [Related]
6. The role of NQO1 polymorphisms in the susceptibility and chemotherapy response of Chinese NSCLC patients.
Tian G; Wang M; Xu X
Cell Biochem Biophys; 2014 Jul; 69(3):475-9. PubMed ID: 24464627
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer.
Zhang T; Zhang DM; Zhao D; Hou XM; Yang TN
J BUON; 2014; 19(3):742-8. PubMed ID: 25261661
[TBL] [Abstract][Full Text] [Related]
8. OPN gene polymorphisms influence the risk of knee OA and OPN levels in synovial fluid in a Chinese population.
Jiang Y; Yao M; Liu Q; Zhou C
Arthritis Res Ther; 2013 Jan; 15(1):R3. PubMed ID: 23289928
[TBL] [Abstract][Full Text] [Related]
9. OPN polymorphism is associated with the susceptibility to cervical spondylotic myelopathy and its outcome after anterior cervical corpectomy and fusion.
Wu J; Wu D; Guo K; Yuan F; Ran B
Cell Physiol Biochem; 2014; 34(2):565-74. PubMed ID: 25116355
[TBL] [Abstract][Full Text] [Related]
10. Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC.
Wu F; Hu N; Li Y; Bian B; Xu G; Zheng Y
Cell Oncol (Dordr); 2012 Jun; 35(3):175-80. PubMed ID: 22476961
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma.
Dong QZ; Zhang XF; Zhao Y; Jia HL; Zhou HJ; Dai C; Sun HJ; Qin Y; Zhang WD; Ren N; Ye QH; Qin LX
Hepatology; 2013 Mar; 57(3):1024-34. PubMed ID: 23079960
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis.
Chen Y; Liu H; Wu W; Li Y; Li J
J Exp Clin Cancer Res; 2013 Jul; 32(1):45. PubMed ID: 23883434
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
[TBL] [Abstract][Full Text] [Related]
14. Association between promoter polymorphisms of OPN gene and cancer risk: a meta-analysis.
Liu J; He C; Yuan Q; Wang Z; Xing C; Yuan Y
Onco Targets Ther; 2016; 9():87-97. PubMed ID: 26766914
[TBL] [Abstract][Full Text] [Related]
15. FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer.
Fang HM; Tian G; Zhou LJ; Zhou HY; Fang YZ
Acta Pharmacol Sin; 2013 Apr; 34(4):549-54. PubMed ID: 23524567
[TBL] [Abstract][Full Text] [Related]
16. [Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens].
Fan HJ; Yuan J; Wu JJ; Jia YX; Ma YH; Li XY
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):99-104. PubMed ID: 30669746
[No Abstract] [Full Text] [Related]
17. The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
Geng N; Su J; Liu Z; Ding C; Xie S; Hu W
Technol Cancer Res Treat; 2021; 20():15330338211019433. PubMed ID: 34060368
[TBL] [Abstract][Full Text] [Related]
18. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer.
Du Y; Su T; Zhao L; Tan X; Chang W; Zhang H; Cao G
PLoS One; 2014; 9(6):e99843. PubMed ID: 24933103
[TBL] [Abstract][Full Text] [Related]
19. Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small-cell lung cancer patients.
Wu F; Zhang J; Hu N; Wang H; Xu T; Liu Y; Zheng Y
Cancer Epidemiol; 2014 Dec; 38(6):728-32. PubMed ID: 25246379
[TBL] [Abstract][Full Text] [Related]
20. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer.
Chang YS; Kim HJ; Chang J; Ahn CM; Kim SK; Kim SK
Lung Cancer; 2007 Sep; 57(3):373-80. PubMed ID: 17513004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
